Ticagrelor in Clopidogrel Resistant Patients Undergoing Chronic Hemodialysis
Status:
Completed
Trial end date:
2012-02-01
Target enrollment:
Participant gender:
Summary
Clopidogrel administration is commonly prescribed in patients undergoing percutaneous
coronary intervention, in patients with previous stroke and in patients under chronic
hemodialysis via fistulae. Patients with chronic renal failure present lower clopidogrel
response compared to those with normal renal function. Ticagrelor is a new oral direct-acting
antagonist, which provides greater platelet inhibition in both clopidogrel responders and
non-responders. It has also been shown that in patients with chronic kidney disease
(creatinine clearance <60 mL/min)ticagrelor achieved an absolute risk reduction of
cardiovascular death, myocardial infarction, and stroke greater than that of patients with
normal renal function. Clopidogrel resistant patients as assessed by VerifyNow
P2Y12(Accumetrics)will be administered after informed consent ticagrelor 90 mg twice daily
for 15 days. Platelet reactivity will be determined at the end of the treatment period.
Bleeding events, major adverse cardiac events and any side effects until Day 15 will be
reported in a descriptive manner.